vimarsana.com

Page 24 - நிறுவனம் ஆஃப் உயிரியல் ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Push for COVID-19 vaccine patent waiver isn t a panacea: but it could nudge companies to share

Sinopharm Efficacy Rate: China s COVID-19 Vaccine Gets WHO Approval for Adult Emergency Use | HNGN

By   May 08, 2021 02:56 AM EDT (Photo : Getty Images/Raul Sifuentes) LIMA, PERU - FEBRUARY 15: View of vials of the Sinopharm vaccine at Ricardo Palma clinic on February 15, 2021 in Lima, Peru. The clinic received a batch of Sinopharm vaccines in order to vaccinate health wokers as part Peru s vaccination campaign against COVID-19. The WHO has approved the COVID-19 vaccine developed by Chinese state-owned company Sinopharm for emergency use. It is the first vaccine created by a non-Western country to receive WHO support. Sinopharm Vaccine Estimated to Be 79% The novel coronavirus vaccine is the first Chinese dose to receive the WHO s green light. The United Nations health agency signed off on the two-shot vaccine. It is already being disseminated in dozens of countries around the globe.

WHO panel okays emergency use of China s Sinopharm COVID-19 vaccine

0 shares FILE - In this Jan. 19, 2021 file photo, a medical worker poses with a vial of the Sinopharm s COVID-19 vaccine in Belgrade, Serbia (AP Photo/Darko Vojinovic, file) GENEVA (AP) The World Health Organization gave emergency use authorization Friday to a COVID-19 vaccine manufactured by China’s Sinopharm, potentially paving the way for millions of the doses to reach needy countries through a UN-backed program rolling out coronavirus vaccines. The decision by a WHO technical advisory group a first for a Chinese vaccine opens the possibility that Sinopharm’s offering could be included in the UN-backed COVAX program in coming weeks or months and distributed through UNICEF and the WHO’s Americas regional office.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.